Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Items 401–500 of 624
Zhang, Y., Wang, Y., Chen, Y., Ding, X., Wang, S., Liu, W., Hu, M., & Liu, Z. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01151 · Cited by 6
Statistical Methods for Drug Discovery
Kühn, M., Yates, P. D., & Hyde, C. L. (2016) · Statistics for biology and health · doi:10.1007/978-3-319-23558-5_4 · Cited by 6
Chakraborty, C., Mallick, B., Sharma, A. R., Sharma, G., Jagga, S., Doss, C. G. P., Nam, J., & Lee, S. (2017) · PubMed Central · doi:10.22074/cellj.2016.4865 · Cited by 7
Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors
Naveed, H., Reglin, C., Schubert, T. E. O., Gao, X., Arold, S. T., & Maitland, M. L. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.05.006 · Cited by 6
Ligand–Receptor Binding Kinetics in Drug Design
Borisov, D. V., & Veselovsky, A. V. (2020) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075082003004x · Cited by 6
Cooper, T. (2023) · FEMS Yeast Research · doi:10.1093/femsyr/foac065 · Cited by 5
Recent Trends in Biomarker Research and Development
Hagen, T. J. (2012) · Biochemistry & Analytical Biochemistry · doi:10.4172/2161-1009.1000e108 · Cited by 6
Brigo, A., & Muster, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12321-2 · Cited by 6
Research and Testing Without Animals: Where Are We Now and Where Are We Heading?
Härtung, T. (2019) · BRILL eBooks · doi:10.1163/9789004391192_029 · Cited by 9
Kenakin, T. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.007 · Cited by 6
The Use of In Silico Models Within a Large Pharmaceutical Company
Brigo, A., & Muster, W. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3609-0_20 · Cited by 6
Animal Models for Cardiovascular Research
Chen, L., Shannon, R. P., & Shen, Y. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00008-7 · Cited by 6
Impact of Biomarkers on Clinical Trial Risk
Reid, G. G. J., Yameen, T. A. B., & Parker, J. L. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.167 · Cited by 6
Marketing authorisation of new medicines in the EU: towards evidence-based improvement
Putzeist, M. (2013) · Utrecht University Repository (Utrecht University) · Cited by 9
F.O.R.W.A.R.D: A Data-Driven Framework for Network-Based Target Prioritization in Drug DiscoveryPreprint
Sinha, S., McLaren, E., Mullick, M., Penrose, H. M., Tindle, C., Singh, S., Boland, B. S., & Ghosh, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.16.602603 · Cited by 6
Developing Treatments for Pulmonary Arterial Hypertension
Wilkins, M. R. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.109961 · Cited by 5
Landeck, L., Lessl, M., Reischl, J., Busch, A. E., Carrigan, P. E., Gottwald, M., Reinke4, P., & Asadullah, K. (2016) · Advances in Precision Medicine · doi:10.18063/apm.2016.01.002 · Cited by 5
Wong, H., & Gould, S. E. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.08.003 · Cited by 5
Saito, R., & Nakada, T. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101019 · Cited by 6
Portfolio Decisions in Early Development: Don’t Throw Out the Baby with the Bathwater
Herschel, M. B. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03256895 · Cited by 5
Clinical trials in the age of personalized medicine
Keating, P., & Cambrosio, A. (2011) · Journal of Medicine and the Person · doi:10.1007/s12682-011-0094-6 · Cited by 5
Kaur, H., Jajodia, A., Grover, S., Agarwal, N., Baghel, R., & Kukreti, R. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.113 · Cited by 5
Developing Microphysiological Systems for Use as Regulatory Tools - Supplementary File
Andersen, M. E. (2014) · ALTEX · doi:10.14573/altex.1405151s · Cited by 5
Breast Cancer Drug Repurposing a Tool for a Challenging Disease
Malik, J. A., Jan, R., Ahmed, S., & Anwar, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101378 · Cited by 10
Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models
Brigo, A., Naga, D., & Muster, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1960-5_24 · Cited by 5
Colin, P., Delattre, M., Minini, P., & Micallef, S. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1295248 · Cited by 5
Death of Drugs and Rebirth of Health Care: Indian Response to Discovery Impasse
Patwardhan, B. (2014) · Wiley eBooks · doi:10.1002/9781118778166.ch12 · Cited by 5
Engineering in vitro complex pathophysiologies for drug discovery purposes
Gaspar, D., & Zeugolis, D. I. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.007 · Cited by 5
Friction and Decision Rules in Portfolio Decision Analysis
Summers, G. J. (2021) · Decision Analysis · doi:10.1287/deca.2020.0421 · Cited by 4
Overview of drugs approved by the FDA in 2022
Куркин, Д. В., Morkovin, E. I., Bakulin, D. A., Gorbunova, Y. V., Kolosov, Y. A., Dzhavakhyan, M. A., Макаренко, И. Е., Васильевич, Д. Р., Zaborovsky, A. V., Shatalova, O. V., et al. (2023) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-3-193-210 · Cited by 4
Strategic Management for Innovation in Life Sciences: A Comprehensive Overview
Saha, S., Hannothiaux, V., Sarkar, M., & Ameloot, S. (2024) · Management for professionals · doi:10.1007/978-3-031-47768-3_11 · Cited by 4
Kim, H.-S., Ryu, C. H., Lee, M., Lee, K., & Kim, J. H. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02890-1 · Cited by 4
Colin, P., Micallef, S., Delattre, M., Mancini, P., & Parent, É. (2015) · Statistics in Medicine · doi:10.1002/sim.6548 · Cited by 4
Pauli, C., Moch, H., & Rubin, M. A. (2017) · doi:10.7892/boris.110750 · Cited by 4
Key role of publication of clinical data for target validation
Hayes, A. G. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.163 · Cited by 4
Asada, R., Shimizu, S., Ono, S., Ito, T., Shimizu, A., & Yamaguchi, T. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12064 · Cited by 4
Reducing the average number of patients needed in a phase II trial through novel design
Wason, J. M. S. (2013) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2013.854802 · Cited by 4
General Introduction on Pharmaceuticals
Eichhorn, P. (2013) · Comprehensive analytical chemistry · doi:10.1016/b978-0-444-62657-8.00001-x · Cited by 4
Non-Specificity of Drug-Target Interactions – Consequences for Drug Discovery
Maggiora, G. M., & Gokhale, V. M. (2016) · ACS symposium series · doi:10.1021/bk-2016-1222.ch007 · Cited by 5
Bass, A. S., Pugsley, M. K., Sannajust, F. J., Yoshinaga, T., & Valentin, J. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106593 · Cited by 4
Mining Complex Biomedical Literature for Actionable Knowledge on Rare Diseases
Alves, V. M., Capuzzi, S. J., Baker, N., Muratov, E. N., Tropsha, A., & Hickey, A. J. (2020) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-32857-3_4 · Cited by 4
Animal Models for Cardiovascular Research
Shen, Y., Chen, L., Testani, J. M., Regan, C. P., & Shannon, R. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00006-1 · Cited by 4
Drug development for chronic lung disease ‐ Mission impossible?
Ask, K., & Kolb, M. R. J. (2014) · Respirology · doi:10.1111/resp.12445 · Cited by 4
Rotroff, D. M., Thomas, R. J., Breen, M., & Motsinger‐Reif, A. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.178 · Cited by 4
GENDER – Zeitschrift für Geschlecht, Kultur und Gesellschaft
Netzwerk Frauen- und Geschlechterforschung, N. R. W., & Geschlechterforschung, N. R. W. (2026) · GENDER – Zeitschrift für Geschlecht Kultur und Gesellschaft · doi:10.3224/gender · Cited by 4
Popović, L., Brankatschk, B., Palladino, G., Rossner, M. J., & Wehr, M. C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117523 · Cited by 3
The use of phase 2 interim analysis to expedite drug development decisions
Huang, J., Das, A., Burger, H. U., Zhong, W. H., Zhang, W., & Liebérman, G. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.05.006 · Cited by 3
Greek, R. (2014) · Biological Systems Open Access · doi:10.4172/2329-6577.1000124 · Cited by 3
Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening
Williams, J. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_10 · Cited by 3
Мирошниченко, А. Г., Булгакова, Ю. С., Perfilev, V. Y., & Базарнова, Н. Г. (2017) · Regulatory Mechanisms in Biosystems · doi:10.15421/021790 · Cited by 3
Are there relevant animal models to set research priorities in LUTD? ICI‐RS 2019
Andersson, K., Birder, L. A., Chermansky, C., Chess‐Williams, R., & Fry, C. H. (2020) · Neurourology and Urodynamics · doi:10.1002/nau.24259 · Cited by 3
Role of Biomarkers in Personalized Medicine
Islam, S. U., Ahmed, M. B., Ahsan, H., & Lee, Y. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_10 · Cited by 7
Lim, H., & Bae, K. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.427 · Cited by 3
Richards, D. B. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04227.x · Cited by 3
Baribault, H., Majeti, J. Z., Ge, H., Wang, J., Xiong, Y., Gardner, J., Li, Y., Gupte, J., Gong, Y. Q., Pan, Z., et al. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.968128 · Cited by 3
Endogenous Toxins as Disease Initiating Events: Future Targets of Drug Discovery Research
Vangala, S. (2016) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2016.02.00036 · Cited by 3
Integrating Biomarkers in Early-Phase Trials
Parchment, R. E., Ferry‐Galow, K. V., & Doroshow, J. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812512-0.00008-7 · Cited by 4
Mechanistic Image-Based Modelling: Concepts and Applications
Menshykau, D., & Tanaka, S. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_328 · Cited by 3
Synthetic human livers for modeling metabolic diseases
Tafaleng, E. N., Malizio, M. R., Fox, I. J., & Soto–Gutiérrez, A. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000726 · Cited by 3
Alternative Models in Drug Discovery and Development Part I: In Silico and In Vitro Models
Romero, L. I., & Vela, J. M. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch02 · Cited by 3
Challenges and Options for Drug Discovery
Kramer, W. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch6 · Cited by 4
3D-Pharma: uma ferramenta para triagem virtual baseada em fingerprints de farmacóforos
Domingues, B. F. (2012) · Americanae (AECID Library) · Cited by 3
Expanding precompetitive space
(2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3602 · Cited by 3
Maji, D., Wolke, M. L., Khaja, S., Savaryn, J. P., Kalvass, J. C., & Jenkins, G. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-86919-7 · Cited by 2
Cader, J. M. A., Newton, M. A. H., & Sattar, A. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108862 · Cited by 2
Xu, Y., Xiao, X. H., & Lin, W. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109053 · Cited by 2
The role of drug metabolism in drug discovery and development : case ospemifene
Uusitalo, J. (2015) · Cited by 2
Discovery and Preclinical Work
Mochly‐Rosen, D., & Grimes, K. (2013) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-3-319-02201-7_2 · Cited by 2
Dong, X., Gout, P. W., Yi, L., Wang, Y., Xu, Y., & Yang, K. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_11 · Cited by 2
Application of In Silico Drug Repurposing in Infectious Diseases
Kumar, P., & Ghosh, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00015-8 · Cited by 2
Saito, R. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.124 · Cited by 2
Hersh, W. (2020) · Health informatics · doi:10.1007/978-3-030-47686-1_2 · Cited by 2
Schmidt, A., Balitzki, J., Grmaca, L., Vogel, J. K., Boehme, P., Boden, K., Hüser, J., Truebel, H., & Mondritzki, T. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10264-4 · Cited by 2
MMV006087 is a potent Malaria Box compound against Plasmodium falciparum clinical parasites
Chirawurah, J. D., Adikah, B., Ansah, F., Laryea-Akrong, E., Danwonno, H. A., Morang’a, C. M., Dosoo, D., Amenga-Etego, L. A., Awandare, G. A., & Aniweh, Y. (2023) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2023.1190471 · Cited by 2
Designing innovative therapies for neuropathic pain: pros and cons of target‐based drug discovery
Inglese, J. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12079_3 · Cited by 2
Chico, L. K., & Watterson, D. M. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.733692 · Cited by 2
Molecular Biomarkers in Clinical Development: What Could we Learn from the Clinical Trial Registry?
Deyati, A., Sanam, R. D., Guggilla, S. R., Pidugu, V. R., & Novac, N. (2014) · Personalized Medicine · doi:10.2217/pme.14.27 · Cited by 2
Brain, P., Strimenopoulou, F., Diukova, A., Berry, E., Jolly, A. J., Hall, J., Wise, R. G., Ivarsson, M., & Wilson, F. J. (2014) · Physiological Measurement · doi:10.1088/0967-3334/35/12/2459 · Cited by 3
In silico predictions of genotoxicity for aromatic amines
Bentzien, J. (2014) · Frontiers in bioscience · doi:10.2741/4233 · Cited by 2
From Mice to Men: Translation from Bench to Bedside
Martić-Kehl, M. I., & Schubiger, P. A. (2016) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781118865064.ch13 · Cited by 2
Drug Discovery: Current State and Future Prospects
Prabu, S. L. (2018) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-7326-5.ch001 · Cited by 4
Applications of Metabolic Phenotyping in Pharmaceutical Research and Development
Everett, J. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812293-8.00014-1 · Cited by 3
The Changing Face of Innovation in Drug Discovery
Zhang, L., & Decicco, C. P. (2014) · Wiley eBooks · doi:10.1002/9781118778166.ch4 · Cited by 2
Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing
Ocaña, A., Šeruga, B., & Amir, E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5699 · Cited by 2
Current and Future Strategies for Improving Drug Discovery Efficiency
Njogu, P., & Chibale, K. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch11 · Cited by 2
Compound Attrition in Phase II/III
Alex, A., Harris, C., Keighley, W. W., & Smith, D. A. (2015) · doi:10.1002/9781118819586.ch4 · Cited by 2
Emerging Technologies and their Role in Regulatory Review
Colatsky, T. J. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch1 · Cited by 2
A multi-center study on factors influencing the reproducibility of in vitro drug-response studiesPreprint
Niepel, M., Hafner, M. A., Mills, C. E., Subramanian, K., Williams, E. H., Chung, M., Gaudio, B. L., Barrette, A. M., Stern, A. D., Hu, B., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/213553 · Cited by 2
Patient-Derived Xenografts From Lung Cancer and Their Potential Applications
Wang, L., Zhang, R., & Fang, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00020-5 · Cited by 1
Applications of Neuroimaging Biomarkers in CNS Drug Development
Cole, P. E., & Einstein, S. G. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00009-6 · Cited by 2
MSFDTA: Predicting drug target affinity based on multi-scale features and adaptive fusion
Huang, W., Tian, X., Su, Y., & Lv, X. (2024) · International Conference on Electrical, Mechanical and Computer Engineering (ICEMCE) · doi:10.1109/icemce64157.2024.10862257 · Cited by 1
High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024
Serafim, R. A. M., & Gehringer, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00293 · Cited by 2
Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Stromatt, J. C., Ahmed, E., Drabison, T., Nepal, M. R., Chowdhury, A. T., Orwick, S. J., Buelow, D. R., Eisenmann, E. D., Huang, K. M., Sparreboom, A., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0265 · Cited by 1
Dyer, A., Dudley, R., Ahuja, S., Alsinet, C., Poudel, P., Bowyer, G., Sahota, K., Songvilay, S., Jones, D. C., Glover, M. S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30224-w · Cited by 1
Effect of pH on small-molecule inhibitor binding to influenza virus hemagglutinin
Anirudhan, V., Gaisina, I. N., Shimon, A., Lee, H., Alqarni, S., Manicassamy, B., Moore, T. W., Xu, K., Caffrey, M. S., & Rong, L. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111150 · Cited by 1
Cheng, Y., Kong, J., Liu, X., & Li, S. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s586786 · Cited by 4
Yokoi, T. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.144.22 · Cited by 1
Villain of Molecular Biology: Why are we not reproducible in research?
Bhardwaj, V. (2015) · F1000Research · doi:10.12688/f1000research.6854.1 · Cited by 2
Hutson, A. D., & Wilding, G. E. (2012) · Pharmaceutical Statistics · doi:10.1002/pst.529 · Cited by 2
Development of Targeted Agents and Companion Diagnostics
Gérard, B., Bétard, M.-C., Smith, B., & Denyer, M. (2012) · Drug Information Journal · doi:10.1177/0092861512444032 · Cited by 1
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.